A next-generation proteasome inhibitor (PI)
Catalog #: B2195 | abID:

Product Details

Alternate Name 4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid; ixazomib citrate
Appearance Off-white solid
CAS # 1239908-20-3
Molecular Formula C₂₀H₂₃BCl₂N₂O₉
Molecular Weight 517.12
Purity ≥98% by HPLC
Solubility DMSO
InChi InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1
PubChem CID 56844015
Handling Protect from air and light
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


MLN-9708 is a prodrug of Ixazomib citrate (MLN-2238). MLN-9708 is an orally bioavailable next-generation proteasome inhibitor (PI) with potential potent anticancer activity in both hematologic and solid tumor xenograft models with better pharmacokinetic and pharmacodynamic features than PS-341 (Cat. No. 1846).

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.